Prospective validation of LungCanSeek and a peer-reviewed economic analysis of U.S. colorectal cancer screening highlight SeekIn’s research on accessible cancer detection
SAN DIEGO, Calif. — SeekIn Inc., an oncology diagnostics company developing blood-based tests for cancer early detection and monitoring, today announced that it will present two posters at the Early Detection of Cancer Conference (EDCC) 2026, October 6–8 in Edinburgh, UK. The conference is hosted by Cancer Research UK, the German Cancer Research Center (DKFZ), and the OHSU Knight Cancer Institute.
The presentations highlight two complementary areas of SeekIn’s early detection research: the clinical validation of LungCanSeek as a blood-based adjunct to LDCT-based lung nodule assessment, and a health-economic analysis of colorectal cancer (CRC) screening strategies in the United States, recently published in Frontiers in Oncology.
LungCanSeek as an Adjunct to Lung-RADS
SeekIn will present results from a prospective study evaluating LungCanSeek in patients with LDCT-detected pulmonary nodules. LungCanSeek combines four protein tumor markers with age and sex to provide additional cancer-risk information.
When used as an adjunct to Lung-RADS, LungCanSeek increased the modeled sensitivity for lung cancer detection from 57.1% to 70.1% in the prospective study. A separate simulation using data from more than one million LDCT examinations in the American College of Radiology’s Lung Cancer Screening Registry showed a similar potential for improving cancer detection through LungCanSeek-informed nodule risk stratification.
The findings build on previous multicenter validation of LungCanSeek and support its continued evaluation as a complementary blood-based tool alongside imaging for lung cancer detection.
Economic Evaluation of Colorectal Cancer Screening Strategies
SeekIn will also present a study published in Frontiers in Oncology (DOI: 10.3389/fonc.2026.1888178) evaluating the performance and economic implications of different CRC screening strategies in the United States.
The analysis compared colonoscopy with FIT, stool-based molecular tests, and blood-based screening tests. The study found that FIT-first screening could reduce projected annual U.S. CRC screening costs by approximately 94.5%, representing an estimated $22.4 billion in annual savings compared with a colonoscopy-first strategy.
The findings highlight the potential of accessible, non-invasive screening approaches to expand CRC screening while reducing pressure on colonoscopy capacity and healthcare resources.
SeekIn Perspective
“Together, these two studies reflect our broader goal at SeekIn: making cancer detection more accessible and practical at population scale,” said Dr. Mao Mao, Founder and CEO of SeekIn. “LungCanSeek demonstrates the potential of blood-based biomarkers to complement imaging-based assessment of pulmonary nodules, while our colorectal cancer analysis highlights the potential of cost-effective screening strategies to expand access and improve the efficiency of healthcare resources. We are pleased to share these findings at EDCC with the international early detection community.”
Conference Details
Early Detection of Cancer Conference (EDCC) 2026
October 6–8, 2026
Edinburgh, UK
Hosted by Cancer Research UK, the German Cancer Research Center (DKFZ), and the OHSU Knight Cancer Institute.
More information: https://www.earlydetectionresearch.com